Upregulation of Peroxiredoxin-2 in Well-Differentiated Pancreatic Neuroendocrine Tumors and Its Utility as a Biomarker for Predicting the Response to Everolimus

Pancreatic neuroendocrine neoplasms (pNENs) account for 2–3% of pancreatic malignancies. Peroxiredoxins (Prdxs), which are major cellular antioxidants, are involved in multiple oncogenic signaling pathways. We investigated the role of peroxiredoxin-2 in QGP-1 human pNEN cell line and patient-derived...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Eui Joo Kim, Yoon Jae Kim, Hye In Lee, Seok-Hoo Jeong, Hyo Jung Nam, Jae Hee Cho
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	MDPI AG 2020-11-01
Ráidu:	Antioxidants
Fáttát:	pancreatic neuroendocrine neoplasm peroxiredoxin mTOR inhibitor everolimus
Liŋkkat:	https://www.mdpi.com/2076-3921/9/11/1104
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!